Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Dr. Flinn on CAR T-Cell Therapy in Non-Hodgkin Lymphoma

July 11th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses chimeric antigen receptor (CAR) T-cell therapy in non-Hodgkin lymphoma (NHL).

PFS Valid Surrogate Endpoint for Overall Survival in Frontline DLBCL

July 11th 2018

Progression-free survival appears to be a surrogate endpoint for overall survival in patients undergoing first-line treatment for diffuse large B-cell lymphoma, according to results from a large pooled analysis.

Dr. Abramson Discusses Lisocabtagene Maraleucel in NHL

July 10th 2018

Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses lisocabtagene maraleucel (JCAR017; liso-cel) as a treatment for patients with non-Hodgkin lymphoma.

Pixantrone Falls Short in Phase III B-Cell NHL Trial

July 9th 2018

Combining pixantrone (Pixuvri) with rituximab (Rituxan) failed to improve progression-free survival compared with gemcitabine plus rituximab in patients with aggressive B-cell non-Hodgkin lymphoma.

Axicabtagene Ciloleucel Approaches EU Approval for DLBCL, PMBCL

June 29th 2018

The European Medicines Agency’s CHMP has recommended approval of axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma.

Tisagenlecleucel Nears European Approval for DLBCL, ALL

June 29th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of tisagenlecleucel for the treatment of either adult patients with diffuse large B-cell lymphoma that is relapsed or refractory after 2 or more lines of systemic therapy, or patients up to 25 years of age with B-cell acute lymphoblastic leukemia that is refractory, in relapse posttransplant, or in second or later relapse.

FDA Grants Ibrutinib/Rituximab Priority Review for Waldenstrom Macroglobulinemia

June 25th 2018

The FDA has granted a priority review to a supplemental new drug application for ibrutinib for use in combination with rituximab as a treatment option across all lines of therapy for patients with Waldenström macroglobulinemia.

Expert Discusses Venetoclax Potential in MCL

June 22nd 2018

Toby Eyre, MBChB, MRCP, discusses the results of the phase I study with venetoclax in patients with poor-risk relapsed/refractory mantle cell lymphoma.

Novel Targeted Antibody-Drug Conjugates in Non-Hodgkin Lymphoma

June 18th 2018

Antibody-drug conjugates represent a targeted class of agents with an improved therapeutic index over traditional chemotherapy in the treatment of non-Hodgkin lymphoma.

Tisagenlecleucel Demonstrates Durable Response Beyond 1 Year in DLBCL

June 17th 2018

At a median follow-up of 14.1 months, the chimeric antigen receptor T-cell therapy tisagenlecleucel achieved an objective response rate of 52% in adult patients with relapsed/refractory diffuse large B-cell lymphoma.

Polatuzumab Vedotin Plus BR Demonstrates Higher PET-CR in DLBCL

June 16th 2018

The addition of polatuzumab vedotin to bendamustine and rituximab induced a higher rate of complete responses by PET scan compared with BR alone in patients with relapsed/refractory diffuse large B-cell lymphoma.

Obinutuzumab/Chlorambucil Solidified as Frontline CLL Option

June 15th 2018

The combination of obinutuzumab and chlorambucil reduced the risk of death by 24% versus rituximab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia with comorbidities.

Flinn Highlights Emerging Combos in Non-Hodgkin Lymphoma

June 15th 2018

Ian Flinn, MD, PhD, discusses the activity and tolerability of 5F9 with rituximab in relapsed/refractory non-Hodgkin lymphoma, as well as intriguing findings with ibrutinib/venetoclax in frontline chronic lymphocytic leukemia.

Update Sustains Liso-Cel as Strong Contender in CAR T-Cell Space

June 14th 2018

The CD19-directed chimeric antigen receptor T-cell therapy lisocabtagene maraleucel (JCAR017; liso-cel) is showing promising response rates in patients with high-risk diffuse large B-cell lymphoma.

CAR T-Cell Therapy: The Sticker Price Is Just for Openers

June 12th 2018

CMS has proposed a different way to handle payment for chimeric antigen receptor T-cell therapy, one that the medical and manufacturing community thinks is unworkable.

Dr. Flinn Discusses Hu5F9-G4 Plus Rituximab in NHL

June 12th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses Hu5F9-G4 (5F9) plus rituximab (Rituxan) in patients with non-Hodgkin lymphoma.

Dr. Abramson Discusses TRANSCEND in Relapsed/Refractory B-Cell Lymphomas

June 8th 2018

Jeremy Slade Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the updated results of the TRANSCEND study in patients with relapsed/refractory b-cell lymphomas.

ASCO Studies Refine CAR T Cell Use

June 7th 2018

Several studies presented at the 2018 ASCO Annual Meeting helped further refine and inform treatment strategies for the budding class of CAR T-cell therapies, with a focus on predicting adverse events and optimizing efficacy.

Rituximab/Lenalidomide Potential Frontline Therapy for Follicular Lymphoma

June 4th 2018

Similar efficacy with the combination of rituximab and lenalidomide coupled with a better safety profile compared with rituximab plus chemotherapy may make the chemo-free regimen a new frontline option for patients with previously untreated follicular lymphoma.

Ibrutinib/Rituximab Reduces Progression Risk by 80% in Waldenstrom Macroglobulinemia

June 2nd 2018

Adding ibrutinib to rituximab lowered the risk of disease progression or death by 80% versus rituximab alone in patients with Waldenström macroglobulinemia.